Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy

被引：0
|
作者：
Paulus, Aneel
Manna, Alak
Wang, Hengbang
Chen, Jianyong
Min, Ping
Yin, Yan
Dutta, Navnita
Halder, Nabanita
Ciccio, Gina
Copland, John
Han, Bing
Bai, Longchuan
Liu, Liu
Wang, Mi
McEachern, Donna
Przybranowski, Sally
Yang, Chao-Yie
Stuckey, Jeanne
Wu, Depei
Li, Caixia
Ryan, Jeremy
Letai, Anthony
Ailawadhi, Sikander
Yang, Dajun
Wang, Shaomeng
Chanan-Khan, Asher
Zhai, Yifan
机构：
来源：
LEUKEMIA & LYMPHOMA | 2023年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1549996
引用
收藏
页码：S79 / S79
页数：1
相关论文
共 50 条
  • [21] Safety and Efficacy of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Relapsed or Refractory (R/R) or Treatment-Naive (TN) Patients (Pts) with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), or Other Myeloid Neoplasms
    Wang, Huafeng
    Wei, Xudong
    Jiang, Qian
    He, Wenjun
    Li, Qiubai
    Liang, Yang
    Weng, Jianyu
    Chen, Suning
    Ma, Hongbing
    Chang, Chukang
    Xu, Yajing
    He, Qun
    Chen, Zi
    Liu, Lihui
    Men, Lichuang
    Cong, Danhua
    Zhang, Zhang
    Yang, Dajun
    Zhai, Yifan
    Jie, Jin
    BLOOD, 2023, 142
  • [22] Inhibition of BCL-2 (by APG-2575) and CDK4/6 synergistically induces cell cycle arrest and apoptosis in ER+ breast cancer.
    Deng, Jing
    Tao, Ran
    Fang, Douglas D.
    Tang, Qiuqiong
    Yin, Yan
    Zhang, Kaixiang
    Li, Yuanbao
    Zhai, Guoqin
    Wang, Qixin
    Yang, Dajun
    Zhai, Yifan
    CANCER RESEARCH, 2021, 81 (13)
  • [23] Phase Ib/II study of BCL-2 inhibitor lisaftoclax (APG-2575) safety and tolerability when administered alone or combined with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor in patients with estrogen receptor-positive (ER plus ) breast cancer or advanced solid tumors
    Kalinsky, Kevin
    Tolcher, Anthony W.
    Wang, Shushen
    Meric-Bernstam, Funda
    Winkler, Robert
    Li, Mingyu
    Sun, Xuemei
    Pan, Wentao
    Paudyal, Bishnuhari
    Liang, Zhiyan
    Lu, Ming
    Yang, Dajun
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [24] FMS-like tyrosine kinase 3 (FLT3) inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor APG-2575 in preclinical models of FLT3-mutant acute myeloid leukemia (AML)
    Fang, Douglas D.
    Zhu, Hengrui
    Tang, Qiuqiong
    Wang, Qixin
    Li, Na
    Fang, Xu
    Min, Ping
    Wang, Guangfeng
    Yang, Dajun
    Zhai, Yifan
    CANCER RESEARCH, 2021, 81 (13)
  • [25] Combination of BCL-2/BCL-xL dual inhibitor APG-1252 and chemotherapeutics overcomes resistance to osimertinib in EGFR mutant NSCLC in preclinical models
    Tao, Ran
    Wang, Guangfeng
    Fang, Douglas D.
    Zhai, Guoqin
    Li, Yuanbao
    Lv, Jing
    Wu, Miaoyi
    Ge, Yangfeng
    Zhang, Feifei
    Wen, Danyi
    Yang, Dajun
    Zhai, Yifan
    CANCER RESEARCH, 2020, 80 (16)
  • [26] BCL-2 inhibitor APG-2575 promotes anti-tumor immunity through converting tumor-associated macrophages into M1 phenotype in non-small cell lung cancer
    Luo, Fan
    Lu, Fei-teng
    Qiu, Miao-zhen
    Pan, Wen-tao
    Zhang, Lin
    Zhao, Hong-yun
    Zhang, Li
    Yang, Da-jun
    CANCER RESEARCH, 2022, 82 (12)
  • [27] Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
    Ailawadhi, Sikander
    Chen, Zi
    Huang, Bo
    Paulus, Aneel
    Collins, Mary C.
    Fu, Lei
    Li, Mingyu
    Ahmad, Mohammad
    Men, Lichuang
    Wang, Hengbang
    Davids, Matthew S.
    Liang, Eric
    Mekala, Divya J.
    He, Zhicong
    Lasica, Masa
    Yannakou, Costas K.
    Parrondo, Ricardo
    Glass, Laura
    Yang, Dajun
    Chanan-Khan, Asher
    Zhai, Yifan
    CLINICAL CANCER RESEARCH, 2023, 29 (13) : 2385 - 2393
  • [28] Embryonic Ectoderm Development (EED) Inhibitor APG-5918 Demonstrates Robust Antitumor Activity in Preclinical Models of T-Cell Lymphomas (TCLs)
    Liang, Zhiyan
    Yin, Yan
    Guo, Huanshan
    Li, Baisong
    Yang, Dajun
    Zhai, Yifan
    BLOOD, 2024, 144 : 1415 - 1416
  • [29] Antitumor Activity of Dual BCL-2/BCL-Xl Inhibitor Pelcitoclax (APG-1252) in Natural Killer/T-Cell Lymphoma (NK/TCL)
    Wang, Guangfeng
    Liang, Eric
    Ming, Ping
    Rui, Li
    Tang, Chunyang
    Lv, Jing
    Ge, Yangfeng
    Zhang, Fei
    Wang, Lvcheng
    Shang, Jingjin
    Yang, Dajun
    Zhai, Yifan
    BLOOD, 2021, 138
  • [30] The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation
    Luo, Fan
    Li, Han
    Ma, Wenjuan
    Cao, Jiaxin
    Chen, Qun
    Lu, Feiteng
    Qiu, Miaozhen
    Zhou, Penghui
    Xia, Zengfei
    Zeng, Kangmei
    Zhan, Jianhua
    Zhou, Ting
    Luo, Qiuyun
    Pan, Wentao
    Zhang, Lin
    Lin, Chaozhuo
    Huang, Yan
    Zhang, Li
    Yang, Dajun
    Zhao, Hongyun
    CELLULAR & MOLECULAR IMMUNOLOGY, 2024, 21 (01) : 60 - 79
12345